Drug Interaction Report

Digoxin and Pirtobrutinib: Interaction Details

A pharmacist-reviewed analysis of the Digoxin and Pirtobrutinib interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Digoxin

Cardoxin® Digitek Digitek® Digox Lanoxicaps® Lanoxin Lanoxin®
+

Pirtobrutinib

Jaypirca Jaypirca®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 453 documented Digoxin interactions, 359 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Increased digoxin exposure and an increased risk of digoxin-related adverse effects

Interaction Deep Dive

Coadministration of pirtobrutinib and digoxin (a P-gp substrate with NTI) increased the exposure of digoxin, which may increase the risk of adverse reactions related to P-gp substrates for drugs which are sensitive to minimal concentration changes. In a drug interaction study, a single 200 mg dose of pirtobrutinib increased the AUC and Cmax of digoxin (a sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and Cmax of digoxin up to 35% and 55%, respectively3. Monitor digoxin exposure and monitor for potential signs and symptoms of clinical toxicity when initiating, adjusting, or discontinuing pirtobrutinib 12.

Why it happens (mechanism)

Inhibition of P-gp-mediated efflux transport of digoxin

Literature reports

1 report — tap to read

a) In a drug interaction study, a single 200 mg dose of pirtobrutinib increased the AUC and Cmax of digoxin (a sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and Cmax of digoxin up to 35% and 55%, respectively 3.

Common questions

Can I take Digoxin and Pirtobrutinib together?

Increased digoxin exposure and an increased risk of digoxin-related adverse effects Always confirm with your pharmacist or prescriber before making any change.

How serious is the Digoxin and Pirtobrutinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Digoxin or Pirtobrutinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (3)

  1. Product Information: DIGOXIN oral tablets, digoxin oral tablets. Aurobindo Pharma USA, Inc. (per Dailymed), East Windsor, NJ, May. DailyMed
  2. Product Information: DIGOXIN intravenous injection, digoxin intravenous injection. Hikma Pharmaceuticals USA Inc. (per Dailymed), Berkeley Heights, NJ, 2023. DailyMed
  3. Product Information: JAYPIRCA(TM) oral tablets, pirtobrutinib oral tablets. Lilly USA LLC (per FDA), Indianapolis, IN, 2023. DailyMed
Was this write-up helpful?
Digoxin

Keep reading about Digoxin

All Digoxin interactions (453) Digoxin drug information
Also serious with: Levoketoconazole Meclofenamate Mavorixafor Parathyroid Hormone Injection
Pirtobrutinib

Keep reading about Pirtobrutinib

All Pirtobrutinib interactions (50) Pirtobrutinib drug information
Also serious with: Colchicine Nifedipine Doxorubicin Midazolam Nasal Spray
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Digoxin + Activated Charcoal Aloe Blue Flag Danshen European Buckthorn Foxglove Indian Snakeroot Lily-of-the-valley + 105 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.